Cargando…
Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia
BACKGROUND: Trigeminal neuralgia (TN) is a rare severe unilateral facial pain condition. Current guidelines in trigeminal neuralgia management recommend sodium channel blockers – carbamazepine or oxcarbazepine – as the first-line treatment. However, the currently available drugs are often associated...
Autores principales: | Zakrzewska, Joanna M, Palmer, Joanne, Ettlin, Dominik A, Obermann, Mark, Giblin, Gerard MP, Morisset, Valerie, Tate, Simon, Gunn, Kevin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222641/ https://www.ncbi.nlm.nih.gov/pubmed/24267010 http://dx.doi.org/10.1186/1745-6215-14-402 |
Ejemplares similares
-
Challenges recruiting to a proof-of-concept pharmaceutical trial for a rare disease: the trigeminal neuralgia experience
por: Zakrzewska, Joanna M., et al.
Publicado: (2018) -
Design of Phase 3 Studies Evaluating Vixotrigine for Treatment of Trigeminal Neuralgia
por: Kotecha, Mona, et al.
Publicado: (2020) -
Analgesic Effects of GpTx-1, PF-04856264 and CNV1014802 in a Mouse Model of Na(V)1.7-Mediated Pain
por: Deuis, Jennifer R., et al.
Publicado: (2016) -
Pain Lateralization in Trigeminal Neuralgia
por: Obermann, Mark
Publicado: (2012) -
Trigeminal neuralgia: a practical guide
por: Lambru, Giorgio, et al.
Publicado: (2021)